Pharmaceuticals
I-Mab Announces Upcoming Participation at January Conferences
SHANGHAI and GAITHERSBURG, MD., Dec. 31, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences inJanuar...
2021-12-31 21:00
3511
China Medical System (867.HK)'s Latest MSCI ESG Rating Unchanged at AA, Leading the Industry Globally
HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company").CMS's latest rating remains uncha...
2021-12-30 20:00
3061
SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical
SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Appro...
2021-12-29 20:30
3083
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...
2021-12-28 22:00
2556
Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS
HONG KONG, Dec. 27, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed. Such clinical trial aims to evalua...
2021-12-28 12:30
2763
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company,announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, smal...
2021-12-28 09:00
1966
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation (CDE) ofChina's National ...
2021-12-27 21:00
2628
Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19
SUZHOU, China, Dec. 27, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatme...
2021-12-27 20:19
3129
Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase
SHANGHAI and WARREN, N.J., Dec. 24, 2021 /PRNewswire/ -- Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the "Emerging Company Showcase" that was held earlier this month inNew York. Dr. Guy Rosenthal, Vice President, Head of C...
2021-12-24 16:30
4241
Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China
BEIJING, Dec. 22, 2021 /PRNewswire/ -- According to Yiling Pharmaceutical's notice onThursday (UTC+8), the Depression-resolving and Restlessness-relieving Capsules have been approved for marketing via the obtained Drug Registration Certificate issued byChina's National Medical Products Administra...
2021-12-23 11:59
2344
Aerogen Pharma Enters into Exclusive Agreements with Nuance Pharma to Advance Treatment of Respiratory Distress Syndrome in Premature Infants in China
SHANGHAI, Dec. 22, 2021 /PRNewswire/ -- Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma ("Nuance"), a specialty care focused biopharma with late-stage clinical programs and existing commercial operations, today announce an exclusive a...
2021-12-23 07:44
3604
AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic Dystrophy
- Additional research centers now enrolling patients in Australia and New Zealand - Company has achieved 50 percent of target enrollment in global Phase 3 trial LONDON, Dec. 23, 2021 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on r...
2021-12-22 21:00
2334
Exopharm Gains US Patent Enabling Commercial Production of Exosome Medicines
* US Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP™ exosome purification technology. * LEAP™ enables large-scale, clinical grade commercial production of exosomes needed to underpin the emerging field of exosome medicines. * Exopharm is seeking potential p...
2021-12-22 19:00
2611
TCM provides new alternatives for the fight against COVID-19
BEIJING, Dec. 21, 2021 /PRNewswire/ -- A news report by haiwainet.cn: During the 18th World Congress of Traditional Chinese Medicine held on4 December 2021, experts fromSpain, France, Australia and other countries and regions highly recognized the role of Traditional Chinese Medicine (TCM) in fig...
2021-12-22 10:15
1924
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population
* The ASTRUM-005 states that serplulimab combined with carboplatin-etoposide prolonged median OS in both the overall population and the Asian subgroup, the median overall survival (OS) in the serplulimab and placebo groups were 15.38 and 11.10 months, respectively, reducing risk of death by 38%...
2021-12-20 22:00
3403
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
- New appointments as part of the Company's strategic development plans to accelerate transformation towards commercialization - Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the Company's R&D organization, focusing on global pipelin...
2021-12-20 21:00
2589
First Patient Dosed in Australia in ATG-101 First-in-Human Trial
SHANGHAI AND HONG KONG, Dec. 19, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and onco...
2021-12-20 10:56
3547
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma
TAIPEI and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...
2021-12-17 20:00
3301
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia
* SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs inSingapore, with launch planned in Singapore in the first quarter of 2022 followed by expansion in conjunction with SAGE Healthcar...
2021-12-16 21:00
3675
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency
TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"),(NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notif...
2021-12-16 21:00
2553
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 320 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 317 media titles]
2026-08-27 10:25
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
18398